Media coverage
3Media coverage
Title FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction Media name/outlet Plus Company Updates (PCU) Country United States Date 10/12/18 Persons Antonio R Anzueto Title FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction Media name/outlet BioSpace Country United States Date 10/11/18 Persons Antonio R Anzueto Title FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction Media name/outlet PharmiWeb Country United Kingdom Date 10/11/18 Persons Antonio R Anzueto